Professor | Kaiyang Ding | Asia Growth Partners

Upload Avatar (500 x 500)

Name

Kaiyang Ding

Contact Information

dingkaiy@ustc.edu.cn

Language ability

Chinese, English

Province

Anhui

University/Lab Affiliation and Title	University of Science and Technology of China
Faculty	Mayo Clinic College of Medicine
Academic Background & Achievements	2003/09–2006/07 Doctorate in Internal Medicine: Suzhou University
Work Experience	2017/12–Present - University of Science and Technology of China, First Affiliated Hospital - Chief Physician

University/Lab Affiliation and Title

University of Science and Technology of China

Faculty

Mayo Clinic College of Medicine

Academic Background & Achievements

Work Experience

2017/12–Present - University of Science and Technology of China, First Affiliated Hospital - Chief Physician

Areas of Focus	Clinical and basic research of malignant lymphoma Clinical and basic research of multiple myeloma
Publications	Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma, Wang X, Yu L, Jiang X, Ding K, 2023 Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial, Ding K, Liu H, Ma J, et al., 2023 Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development, Jiang X, Zhang H, Ni J, Zhang X, Ding K, 2022 The 'm6A writer' METTL3 and the 'm6A reader' IGF2BP2 regulate cutaneous T-cell lymphomas progression via CDKN2A, Wang X, Hu M, Yu L, Wang X, Jiang X, Zhang G, Ding K, 2022 Roles of exosomes in cancer chemotherapy resistance, progression, metastasis and immunity, and their clinical applications (Review), Zhou Y; Ding K; Wang X, 2021

Areas of Focus

Clinical and basic research of malignant lymphoma
Clinical and basic research of multiple myeloma

Publications

Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma, Wang X, Yu L, Jiang X, Ding K, 2023
Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial, Ding K, Liu H, Ma J, et al., 2023
Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development, Jiang X, Zhang H, Ni J, Zhang X, Ding K, 2022
The 'm6A writer' METTL3 and the 'm6A reader' IGF2BP2 regulate cutaneous T-cell lymphomas progression via CDKN2A, Wang X, Hu M, Yu L, Wang X, Jiang X, Zhang G, Ding K, 2022
Roles of exosomes in cancer chemotherapy resistance, progression, metastasis and immunity, and their clinical applications (Review), Zhou Y; Ding K; Wang X, 2021

Malignant Lymphoma Clinical Research Basic Research Hematology Oncology Cancer Lymphoma Treatment Diagnosis Therapy Multiple Myeloma Myeloma

Shandong Ye - University of Science and Technology of China

Tang Qiqiang - University of Science and Technology of China

Weidong Jia - University of Science and Technology of China

View All

Personal Information